Takeda Pharmaceuticals stated that as part of its multi-year plan to support growth and improve profit margins, the company will incur a one-time restructuring fee of 140 billion yen in the 2024 fiscal year, which has been reflected in the full year forecast. Takeda Pharmaceuticals stated that it will include measures to optimize its workforce, and specific details will be provided in& Quota; At the appropriate time& Quota; Decision. (Bloomberg)